Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape

Kirthiga Devi, S.S.; Singh, Sidhartha; Joga, Ramesh; Patil, Sharvari Y.; Meghana Devi, Vakalapudi; Chetan Dushantrao, Sabnis; Dwivedi, Falguni; Kumar, Gautam; Kumar Jindal, Deepak; Singh, Charan; Dhamija, Isha; Grover, Parul; Kumar, Sandeep

doi:10.1016/j.ejpb.2024.114323

European Journal of Pharmaceutics and Biopharmaceutics

2024

DOI: 10.1016/j.ejpb.2024.114323

|View full text |Cite

Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape

S.S. Kirthiga Devi,

Sidhartha Singh,

Ramesh Joga

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 200 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Cabozantinib enhances CAIX specific CAR-T cells against renal cancer by improving effector functions and augmenting tumor immune microenvironment

Li,

Yang,

et al. 2024

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Cabozantinib enhances CAIX specific CAR-T cells against renal cancer by improving effector functions and augmenting tumor immune microenvironment

Li,

Yang,

et al. 2024

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

Winners of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part I

Wang,

Yang

2024

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

The present editorial is a "Part I," focusing on the recent advance of cancer treatment. 1,[6][7][8][9][10] Conventionally, treatment opinions have limited to surgery, radiotherapy, and chemotherapy before. Although the majority of them, if localized tumor or early-stage cancers are diagnosed, can be successfully managed by three aforementioned strategies, there is no doubt that for a substantial number of women presenting with persistent, recurrent and/or metastatic cancers the prognosis is extremely poor, and rarely these advanced cancer patients could have the median overall survival more than 1 year, suggesting that new prognostic information-or personalized biomarkers-driven approach treatment is urgently needed.Herein, we are happy to introduce the exciting works from the "Winners" of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei. In this part I, Dr. Wu and his colleagues won this award for their work entitled "Immunoprofile of adenosquamous carcinoma in gastric cancer" which was published in the June issue of 2023 JCMA. 1 The authors attempted to investigate the immune profile of the rare subtype of gastric cancer in Taiwan to look for the optimal treatment modality. Among the data pool of all gastric cancers, gastric adenosquamous cancer (GASC) presented 0.35% (14/4034) reflecting its real rarity. Their study protocols included the recently very important biomarkers, such as p40, human epidermal growth factor receptor 2 (HER2), Epstein-Barr virus-encoded RNA (EBER), programmed death-ligand 1 (PD-L1) combined positive score (CPS), V-Raf murine sarcoma viral oncogene homolog B (BRAF), and DNA mismatch repair (MMR) proteins (eg, MutL Homolog 1 [MLH1], MutS homolog

show abstract

Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy

Rahman,

Yadab,

Ali

2024

Cells

View full text Add to dashboard Cite

Identifying definitive biomarkers that predict clinical response and resistance to immunotherapy remains a critical challenge. One emerging factor is extracellular acidosis in the tumor microenvironment (TME), which significantly impairs immune cell function and contributes to immunotherapy failure. However, acidic conditions in the TME disrupt the interaction between cancer and immune cells, driving tumor-infiltrating T cells and NK cells into an inactivated, anergic state. Simultaneously, acidosis promotes the recruitment and activation of immunosuppressive cells, such as myeloid-derived suppressor cells and regulatory T cells (Tregs). Notably, tumor acidity enhances exosome release from Tregs, further amplifying immunosuppression. Tumor acidity thus acts as a “protective shield,” neutralizing anti-tumor immune responses and transforming immune cells into pro-tumor allies. Therefore, targeting lactate metabolism has emerged as a promising strategy to overcome this barrier, with approaches including buffer agents to neutralize acidic pH and inhibitors to block lactate production or transport, thereby restoring immune cell efficacy in the TME. Recent discoveries have identified genes involved in extracellular pH (pHe) regulation, presenting new therapeutic targets. Moreover, ongoing research aims to elucidate the molecular mechanisms driving extracellular acidification and to develop treatments that modulate pH levels to enhance immunotherapy outcomes. Additionally, future clinical studies are crucial to validate the safety and efficacy of pHe-targeted therapies in cancer patients. Thus, this review explores the regulation of pHe in the TME and its potential role in improving cancer immunotherapy.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape

Cited by 3 publications

References 200 publications

Cabozantinib enhances CAIX specific CAR-T cells against renal cancer by improving effector functions and augmenting tumor immune microenvironment

Cabozantinib enhances CAIX specific CAR-T cells against renal cancer by improving effector functions and augmenting tumor immune microenvironment

Winners of the 2023 honor awards for excellence at the annual meeting of the Chinese Medical Association-Taipei: Part I

Emerging Role of Extracellular pH in Tumor Microenvironment as a Therapeutic Target for Cancer Immunotherapy

Contact Info

Product

Resources

About